severe headache, coughing up blood or vomiting blood.

Apixaban.

stools, blood in urine, nose-bleed, dizziness, tiredness, paleness or weakness, sudden

• If you need surgery or any invasive procedure, inform your doctor that you are taking

. If the bleeding does not stop on its own, seek medical attention immediately.

72 mm

Back Side

Information for healthcare professionals

- Apixaban is an oral anticoagulant acting by direct selective inhibition of factor Xa.
- Apixaban may increase the risk of bleeding. In case of major bleeding events, it should be stopped immediately.
- Treatment with Apixaban does not require routine monitoring of exposure. A calibrated
 quantitative anti-Factor Xa assay may be useful in exceptional situations, e.g., overdose and
 emergency surgery (prothrombin time (PT), international normalised ratio (INR) and activated
 partial thromboolastin time (aPTT) clotting tests are not recommended) see SmPC.
- . An agent to reverse the anti-factor Xa activity of apixaban is available.

Date of preparation: June 2024

I am under anticoagulation tre	tment with Apixaban to	prevent blood clots.
--------------------------------	------------------------	----------------------

IVAITIG.

Indication:

Dose: mg twice daily

Doctor's Name:

Doctor's telephone:

Area for Item Code

TLPXXXX

34 mm

			Specification	on for Carton	
Product Name:	APIXABAN Tablets 2.5 mg & 5 mg	Revision / New Artwork: New Artwork			
Item :	Patient card	Reasons for Change: NA			
Item Code:	TLPXXXX	Reasons for Change. IVA			
Pharma Code:	XXXX				
Size:	72 x 34 mm (W x H)				
Blister Size:	NA				
GSM/Paper:	300 gsm Art Card				
Varnish:	NA				
Colours:	Black				
EFFECTS:	NA				
BRAIL:	NA	Initiation Date	Revision Date	Revision No.	
Country:	UK	20-08-2024	10-09-2024	03	
Language:	English				

VER 03/ SEP 2024

MHRA approval date: 10/2025